background: Polycystic ovary syndrome (PCOS) is characterized by ovarian dysfunction. The association with obesity and insulin resistance is well established. Steroid hormones play a central role in the regulation of both ovarian function and body composition. This study aims to assess the influence of known functional polymorphisms in genes that are responsible for the production, metabolism and signal transduction of steroid hormones on the susceptibility to and phenotype of PCOS. Functional polymorphic variants were selected in genes that affect the production of estradiol and cortisol [aromatase (CYP19), 11-betahydroxysteroid dehydrogenase type I (HSD11B1) and hexose-6-phosphate dehydogenase (H6PD)] and in genes for signal transduction proteins [estrogen receptor (ESR1 and ESR2) and glucocorticoid receptor (GCR)].
Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women, accounting for nearly 75% of women with anovulatory subfertility (Franks, 1995) . The most important characteristics consist of anovulation, hyperandrogenism and the appearance of PCOs at ultrasound. While twin studies and studies of familial segregation patterns provide convincing evidence for a genetic aetiology, a clear Mendelian inheritance pattern is lacking (Legro, 1999; Vink et al., 2006) . Therefore, PCOS is hypothesized to be the result of an intricate interaction of multiple genetic and environmental factors, i.e. a complex genetic disease.
Besides the ovulatory dysfunction that is often the reason for seeking medical attention, there is a wide variety of metabolic disorders that are frequently found in women with PCOS. These include obesity, insulin resistance and dyslipidemia (Ehrmann et al., 2006; Valkenburg et al., 2008) . Steroid hormones play a central role in the regulation of both ovarian function and body composition. Glucocorticoids (GCs) have numerous effects throughout the human body including on the regulation of fat distribution, and lipid and glucose metabolism. Increased peripheral cortisol metabolism has been reported in association with PCOS, in a manner that is independent of BMI (Rodin et al., 1994; Vassiliadi et al., 2009) . It is hypothesized that a compensatory up-regulation of the hypothalamicpituitary-adrenal (HPA) axis is responsible for the excess of adrenal androgens [dehydroepiandrosterone (DHEA) and DHEA sulphate (DHEAS)] and their urinary excretion metabolites. Peripheral GC metabolism is dependent on the tissue-specific interconversion of cortisol into the non-bioactive steroid cortisone. Two polymorphisms within genes that regulate this enzymatic process [11-beta-hydroxysteroid dehydrogenase type I (HSD11B1) and hexose-6-phosphate dehydrogenase (H6PD)] have been associated with a loss of HSD11B1 oxo-reductase activity, resulting in more efficient conversion of cortisol into its non-bioactive metabolites (Draper et al., 2003) .
The influence of genetic variants of the GCs receptor (GCR) on body composition and metabolism are wide ranging and include BMI, insulin resistance and cholesterol levels (van Rossum et al., 2004a,b; van Rossum et al., 2004) . Polymorphic variants of GCR are associated with both higher and lower GC sensitivity, as demonstrated by a variable suppressive response to 0.25 mg of Dexamethasone (van Rossum et al., 2004) . Interestingly, a non-synonymous coding singlenucleotide polymorphism (SNP) in exon 2 of the GCR (rs6190), which results in a relative GC resistance, has been associated with multiple clinical end-points that seem to indicate a more beneficial risk profile with regard to central adiposity, insulin resistance and lipid profiles (van Rossum et al., 2004a,b) . However, the only study to date examining the influence of a single GCR polymorphism (rs6195) in 114 PCOS cases and 92 controls did not find an association with disease phenotype or susceptibility (Kahsar-Miller et al., 2000) .
Notwithstanding the adrenal contribution to the production of androgens, the ovary remains the primary source of sex steroids in women. Androgens that are produced by follicular theca cells are secreted into follicular fluid where they are converted into estrogens by the action of the enzyme aromatase. A genetic variant (rs10046) of CYP19, the gene that encodes aromatase, was associated with higher expression of mRNA levels in breast cancer tissue and higher risk for breast cancer [odd ratio (OR):1.5] (Kristensen et al., 2000) , possibly due to increased estrogen exposure. Furthermore, estrogen signalling may be affected by polymorphic variants of the estrogen receptor (ESR). There are two forms of ESRs (ESR1 and ESR2) that are expressed in tissue-specific patterns during human development. ESR1 is predominantly expressed in the uterus, while ESR2 is expressed in the ovary, testis, spleen, brain and skin (Brandenberger et al., 1997) . Polymorphic variants of ESR1 have been consistently associated with a number of phenotypes that are related to decreased estradiol (E 2 ) signalling, i.e. increased risk of osteoporosis (van Meurs et al., 2003) , myocardial infarction and stroke , later age at onset of menopause (Weel et al., 1999) and decreased serum E 2 levels in post-menopausal women (Schuit et al., 2005) . Furthermore, an association with ovulatory dysfunction (Sundarrajan et al., 2001) and altered ovarian response to controlled hyperstimulation during IVF has been observed (Sundarrajan et al., 1999; Altmae et al., 2007) .
The aim of the present study is to examine to what extent functional genetic variants of the steroid hormone pathway and GC receptor can alter disease susceptibility and phenotypic characteristics with regard to PCOS.
Materials and Methods

Study population
Anovulatory subjects who attended our infertility outpatient clinic between 1994 and 2004 were eligible for inclusion. Inclusion criteria were oligomenorrhoea (interval between consecutive menstrual periods .35 days) or amenorrhoea (absence of vaginal bleeding for at least 6 months) and serum FSH concentrations within the normal range (1-10 U/l) (van Santbrink et al., 1997; Schipper et al., 1998) . Ethnicity and country of birth were registered. The diagnosis of PCOS was established on the basis of the 2003 ESHRE/ASRM Rotterdam criteria (2004) . In agreement with these criteria, hyperandrogenism was defined as the presence of either biochemical or clinical signs (hirsutism) of androgen excess. For the purpose of this study hirsutism was assessed by means of the Ferriman-Gallway (FG) score, and was defined as FG score ≥8. Biochemical hyperandrogenism was determined by calculation of the free androgen index (FAI) as follows:
where T stands for testosterone and SHBG for sex-hormone binding globulin. A cut-off level of 4.5 was used for the definition of hyperandrogenism (van Santbrink et al., 1997) . The presence of PCOs was detected by vaginal ultrasound examination. PCO was defined as the presence of 12 or more follicles in one or both ovaries, and/or increased ovarian volume (.10 ml). Exclusion criteria were: (i) the presence of related disorders with similar clinical presentation, such as congenital adrenal hyperplasia, hyperprolactinaemia and Cushing's syndrome and (ii) non-Caucasian descent.
The control group was derived from The Rotterdam Study, a singlecentre, prospective, population-based study of determinants of chronic disabling diseases in the elderly, aged 55 years and over (n ¼ 7012). The design of this study has been described previously (Hofman et al., 1991 (Hofman et al., , 2009 . Participants from the Rotterdam study originate from a specific area near Rotterdam (Ommoord) that constitutes a homogeneous population-based sample of Caucasian elderly men and women. Inclusion criteria for the present study were female sex, age at onset of menopause .45 years and available DNA (n ¼ 2996). Written informed consent was obtained from all anovulatory patients as well as controls.
Measurements
Anovulatory patients underwent a standardized initial screening that was performed after an overnight fasting period on a random day between 9 a.m. and 11 a.m. Clinical examination included a structured interview and physical examination. Transvaginal ultrasonography was performed in order to assess ovarian volume and follicle count for both ovaries. Blood samples, taken on the day of clinical examination, were obtained by venipuncture and processed within 2 h after withdrawal. Serum was stored at -208C until assayed. Assays used to measure the endocrine and metabolic parameters were as follows. FSH, LH, SHBG, insulin, cortisol, progesterone, androstenedione and DHEAS were measured in serum by immunoluminescence-based assays (Immulite w platform, Siemens DPC, Los Angeles, CA, USA). DHEA, 17-hydroxy-progesterone, E 2 and testosterone concentrations were assayed using coated tube radioimmunoassays (DPC). Glucose levels were measured using a Hitachi w 917 analyzer (Roche Diagnostics, Almere, the Netherlands). Insulin resistance was estimated by homeostasis model assessment (HOMA). In order to calculate HOMA scores, the updated computer model (HOMA2) was used (Levy et al., 1998) .
Genotyping
Genomic DNA was extracted from peripheral venous blood according to standard procedures. Genotypes were determined using Taqman allelic discrimination assays, designed via the Assay-by-Design service (Applied Biosystems Inc., Foster City, CA, USA). The following polymorphisms were included: four SNPs in GCR ( Primer and probe sequences are available from the authors upon request. The PCR mixture included 2 ng of genomic DNA in a 2 ml volume and the following reagents: probes (200 nM), primers (0.9 mM) and 2×Taqman PCR master mix (ABgene, Epsom, UK). PCR cycling reactions were performed on an ABI 9700 PCR system (Applied Biosystems Inc.) and consisted of initial denaturation at 958C (15 min), and 40 cycles with denaturation (15 s at 958C) and annealing and extension (60 s at 608C). GCR and ESR1 haplotypes were inferred on the basis of Bayesian linkage disequilibrium analysis using the PHASE software package, version 2.1 (Stephens et al., 2001) . Haplotype alleles were coded as numbers (1-3 for ESR1 and 1 -5 for GCR) in order of decreasing population frequency.
Statistical analysis
Genotype and allele frequencies were calculated for all polymorphisms and subsequently tested for Hardy -Weinberg equilibrium (HWE) with Pearson's x 2 test. Cross tables were constructed in order to compare genotypes and allele frequencies between the PCOS population and controls. ORs and 95% confidence interval (CI) were calculated. Medians and interquartile ranges (P25-P75) were calculated in order to describe the distribution of anthropomorphometric data. A non-parametric test (MannWhitney U ) was used for the exploratory comparison of continuous variables between different genotype groups. Variables were checked for normal distributions with the one sample Kolmogorov-Smirnov test and log-transformed if necessary. Analysis of covariance was applied to adjust for age differences. In order to test for allele-dose effects, the between-group variation was tested for linear association. Between-group differences of categorical variables were evaluated by Pearson's x 2 test.
Accounting for the total number of SNPs that were tested (n ¼ 10), the threshold for statistical significance was set at a P-value of ≤0.005. Statistical analysis was performed using SPSS version 12; SPSS Inc., Chicago, USA). Power calculations were performed for a codominant mode of inheritance with one degree of freedom, using the PGA software package version 2.0 (Menashe et al., 2008) . Assuming a minor allele frequency (MAF) of 0.05 and disease prevalence of 5%, we calculated a power of 88% (a 0.05) to detect a relative risk of 1.5 at 500 cases and a case: control ratio of 5:1. Lowering MAF to 0.02, the power was calculated as 53 and 97% to detect relative risks of 1.5 and 2.0, respectively. 
Results
PCOS phenotype
GC receptor polymorphisms
All four polymorphisms of the GC receptor were in HWE in the case group and in controls. GCR genotypes were similarly distributed at all four loci in PCOS cases and controls (Table II) . The phenotype analysis showed 37% higher LH levels in heterozygous carriers of the minor allele (Lys 23 ) of the rs6190 Arg23Lys polymorphism (10.4 versus 7.6 U/l, P ¼ 0.04). FSH levels, androgens and other endocrine and ultrasound parameters were not affected by Lys 23 (Table III) , the minor allele of the rs6198 polymorphism (G 9b ) was associated with a trend towards higher LH levels. LH levels increased by 1.3 U/l per allele copy of G 9b (95% CI: 0.1 -2.6 U/l, P ¼ 0.02). In addition, homozygous carriers of G 9b showed longer menstrual intervals compared with other subjects (53 versus 43 days, P ¼ 0.04). Heterozygous carriers of the rs6195 Ser 363 allele showed a slightly more benign phenotype with regard to obesity (11% lower BMI, P ¼ 0.01) and central adiposity (7% lower waist circumference, P ¼ 0.008). As expected, these changes in body composition were accompanied by lower fasting insulin levels (51 versus 58 pmol/l, P ¼ 0.02) and slightly lower HOMA scores for insulin resistance (0.94 versus 1.06, P ¼ 0.04). Associations of GCR genotypes with the phenotypic characteristics of PCOS did not surpass the more severe threshold for statistical significance (P , 0.005) that was applied to correct for multiple testing.
GCR haplotypes
Call rates for the GCR SNPs varied between 87% (rs6198) and 97% (rs6195 was available for 445 Caucasian PCOS patients and 2755 controls. The degree of correlation between each of the polymorphic variants ranged from 0.001 (r 2 ) to 0.13 (Fig. 1) . Allele-frequencies of the five most common GCR haplotypes were similar in PCOS cases and controls. No single haplotype was associated with risk for PCOS. Haplotype descriptions and allele-frequencies are presented in Fig. 2 . Haplotype 1 (H1), which constitutes the absence of minor alleles at all four loci, was the most frequent haplotype among women with PCOS (allele frequency 40.1%). Homozygous carriers of H1 (n ¼ 79) served as a reference group for the comparison of clinical, ultrasound and endocrine characteristics within the entire PCOS group (results in Table IV) .
Haplotype 2 (H2) constitutes the presence of the minor allele at the rs41423247 locus. The presence of H2 (0, 1 or 2 alleles) was associated with lower LH levels (0.7 U/l per allele copy, P ¼ 0.04) and higher age at the time of study (0.9 years increase per allele copy, P ≤ 0.01). Figure 3 shows median LH levels in association with allelic combinations of GCR haplotypes.
In contrast, the results for haplotype 3 (H3, the presence of the minor allele (G 9b ) of the rs6198 polymorphism) were the opposite of H2, i.e. carriership of one or two copies of the minor allele was associated with significantly higher LH levels (1.2 U/l increase per allele copy, P ¼ 0.05) and lower age (1.2 years decrease per allele copy, P ≤ 0.01). Moreover, homozygous carriers of H3 (n ¼ 14) showed nearly 1.8 times longer menstrual interval compared with non-carriers (mean increase of 6.7 days per allele copy, P ¼ 0.02).
Haplotype 4 (H4), which is characterized by the presence of the minor allele of rs6195 (Ser 363 ), was associated with a more benign metabolic profile. A comparison of H1/H4 carriers with the reference group (H1/H1) showed 10% lower waist circumference (P ¼ 0.03) ( Table IV) . H4 carriers seemed to be less insulin resistant as indicated by lower insulin levels (45 versus 65 pmol/l, P ¼ 0.03); however, fasting glucose levels were higher compared with the reference groups (4.3 versus 4.0 mmol/l, P ≤ 0.01). No significant difference in HOMA score was observed.
HSD11B1 and H6PD
The allele frequencies of the HSD11B1 and H6PD polymorphisms were 21.0 and 24.3%, respectively (Table II) . The HSD11B1 polymorphism was in HWE in PCOS cases and controls, whereas the H6PD polymorphism (rs6688832) showed a significant deviation from equilibrium in PCOS cases (P ¼ 0.03). There were no significant differences in the distribution of the HSD11B1 genotypes between women with PCOS and the controlpopulation. The presence of the minor alleles of HSD11B1 (ins-A) or H6PD (Gln 453 ) did not influence any of the phenotypic characteristics of PCOS patients, including androgens (T, DHEA and DHEAS), levels of gonadotropic hormones (LH and FSH) and cycle history (mean cycle duration, frequency of amenorrhoea) (data not shown). Moreover, no significant differences were observed with regard to Figure 2 Characterization and allele frequencies of GCR haplotypes one to five (allele frequency .1%) in PCOS cases and controls. Steroid hormone polymorphisms in PCOS the presence of PCO, hyperandrogenism, obesity or insulin resistance among women with PCOS (data not shown).
Aromatase (CYP19)
CYP19 rs10046 T/C genotypes were in HWE in PCOS cases and controls. No differences were observed for allele frequencies and genotype distributions in PCOS cases and controls (Table II) . Moreover, we observed no differences in the phenotype of women with PCOS (specifically with regard to androgen and estrogen levels) among different CYP19 genotype groups (data not shown).
Estrogen receptor (ESR1 and ESR2)
All polymorphisms of the ESR1 and ESR2 were in HWE in women with PCOS and controls. Polymorphisms of ESR1 (rs2234693 and rs9340799) and ESR2 (rs4986938) were similarly distributed among PCOS patients and controls (Table II) . No associations with the phenotype of PCOS patients were observed for any of the three SNPs in ESR1 or ESR2 (data not shown).
The two polymorphic variants of ESR1 showed a high level of correlation (r 2 ¼ 0.64) Haplotype 1 (ESR1-H1), which was the most common haplotype of ESR1 among women with PCOS and controls, consisted of a combination of the major alleles of rs2234693 and rs9340799 (T-A). (C-G) and haplotype 3 (C-A) were similar in women with PCOS and controls; 53.4 versus 54.4% (ESR1 H1); 35.9 versus 34.3% (ESR1 H2) and 10.7 versus 11.4% (ESR1 H3). Furthermore, the phenotype of women with PCOS was not affected by any of the three ESR1 haplotypes.
Discussion
Steroid hormones play a central role in the regulation of both ovarian function and body composition with regard to (central) obesity and insulin resistance. Therefore, the primary aim of this study was to investigate whether known functional genetic variants of the steroid hormone pathway affect the phenotype of PCOS patients with regard to disease risk, hyperandrogenism and insulin resistance. The present study is the first to assess the role of these functional polymorphisms of the GC receptor in PCOS patients and controls. While no differences in genotype distribution were identified in PCOS cases and controls, a number of phenotypic associations that may be related to altered GC action were identified. GCR variants were associated with changes in LH levels that suggest an inhibitory influence of the GC receptor on the function of the hypothalamo-pituitary-gonadal axis. We observed higher LH levels in association with the rs6190 and rs6198 polymorphisms. Both variants have been described as negative inhibitors of GCR action in prior research (Oakley et al., 1996; van Rossum et al., 2002) . While these findings are not significant at the 0.005 level (threshold for multiple testing), we did observe significantly higher LH levels in combined carriers of haplotypes three and five, that are associated with one (H3) or both (H5) genetic variants. Our data are consistent with data from the HapMap Project (release 28) in the finding of some correlation between the two polymorphisms (r 2 ¼ 0.12, Fig. 1 ). Therefore, it is difficult to differentiate between the effects of one or the other polymorphic variant on LH levels. H3, that contains only the rs6198 variant, was associated with higher LH levels in a manner that is consistent with an allele dose effect (1.2 U/l per allele copy) (Fig. 3) . Conversely, the analysis of haplotypes two and four showed lower LH levels in association with GC receptor variants that are known to increase receptor sensitivity (rs6195 and rs41423247) (van Rossum et al., 2004) . H2 (the minor allele of rs41423247) was associated with lower serum LH levels (0.7 U/l per allele copy). More so, median LH levels were lowest in patients who carried a combination of H2 and H4 (minor allele of rs6195). Both H2 and H3 were associated with patients' age at the time of study. It is not likely that GCR genotype would have had a direct influence on this parameter; however, age could have acted as a confounder of LH levels. Given the direction of the observed differences, this is not a likely explanation for the associations with LH levels that were found. Because the observations with regard to the phenotype of women with PCOS were not significant at the 0.005 level, we cannot exclude the possibility that they were the result of multiple testing. However, our findings do show consistency and may indeed reflect the relatively small changes in phenotype that are expected to result from receptor polymorphisms that occur frequently in the general population. The present study is limited by the absence of phenotype data in the control population. Therefore, controls could not be selected for the absence of PCOS. As it is known that 5-8% of women in the general population will develop PCOS, we expect that the present results will represent an underestimation of the actual difference in cases and controls. The concomitant loss-of-power will be partially overcome by the relatively large number of patients and controls that were included. Secondly, there is an apparent age difference between controls (.55 years) and PCOS cases of reproductive age. However, it is known that the distribution of genotypes will be stable in subsequent generations of a large population. Therefore, on the condition that the presence of these polymorphisms do not shorten life-span significantly, the higher age of controls is not regarded as a likely confounder.
Animal research has provided convincing evidence for a link between GC action and the production of gonadotropic hormones in rats (Briski, 1996) , ewes (Breen et al., 2008) and rhesus monkeys (Dubey et al., 1985) , either at the pituitary or hypothalamic level. As was found in animal studies, the results of our study indicate that GCs may exert an inhibitory influence on gonadotrophin (LH) release. However, taking into account that the distribution of genotypes was similar in cases and controls, it does not seem likely that these variants contribute to PCOS susceptibility. The question whether these associations are also present in the general population cannot be answered by the present study as we do not have data on gonadotropic hormone levels in controls. It is tempting to speculate that these results point in the direction of a link between the hypothalamo-pituitary-gonadal axis and the HPA axis that is certainly well established in animal studies but not in human studies.
The most pronounced influence on body composition was noted for the GCR rs6195 polymorphism. The presence of the minor allele (Ser 363 ) was associated with lower waist circumference and lower fasting insulin levels among PCOS patients. While significance levels did not surpass the threshold for multiple testing, similar results were obtained from the haplotype analysis for H4. As expected, changes in waist circumference and fasting insulin levels were highly dependent on the differences in BMI between carriers and non-carriers. In contrast, raised glucose levels in H1/H4 carriers did not depend on differences in BMI and are consistent with a diabetogenic action of GCs (Delaunay et al., 1997) . The influence of this polymorphic variant on body composition has been examined in numerous studies showing contradictory results. Lin et al. (1999) found highly significant associations with BMI and obesity in two groups of white Australian subjects. However, no apparent influence on body composition and insulin resistance was found in a Swedish study of 284 men (Rosmond et al., 2001) . Moreover, a recent meta-analysis found no evidence for associations with either BMI or risk of obesity (Marti et al., 2006) . The present study seems to be unique in the finding of lower BMI in carriers of the Ser 363 allele, which may be a specific finding in PCOS patients. The role of the rs6195 polymorphism in PCOS patients has been evaluated before in a case-control study that did not establish any associations with either adrenal androgen excess or disease risk (Kahsar-Miller et al., 2000) . However, the authors provide no information on BMI. Due to the low frequency of this polymorphism in reported PCOS cases (6 of 109 cases), this study may have been severely underpowered. The present study is in agreement with the former, as we do not observe altered disease risk in carriers (or non-carriers) of the minor allele.
